Effects of in-vivo administration of taurine and HEPES on the inflammatory response in rats.
The effect of in-vivo administration of N-2-hydroxyethylpiperazine-N'-2- ethane sulphonic acid (HEPES) and taurine on rat paw oedema and reactive oxidant production was examined. Carrageenan-induced paw oedema was attenuated following intraperitoneal injection of HEPES. Chemiluminescence production by isolated peripheral blood mononuclear cells (PBMC) was reduced in HEPES-treated rats. Taurine-treated rats did not exhibit attenuation of paw oedema using subcutaneous or intraperitoneal administration but intracerebroventricular administration produced a significant reduction at a dosage of 4.0 mumol. No reduction in chemiluminescence production was observed by PBMC using subcutaneous or intraperitoneal administration of taurine, but intracerebroventricular administration produced a significant reduction at a dosage of both 0.4 and 4.0 mumol. Intravenous injection of [14C]HEPES or [3H]taurine demonstrated rapid clearance with a significantly longer half-life of HEPES compared with taurine. These results support previous reports of anti-inflammatory activity of taurine when administered centrally. The lack of anti-inflammatory effect when taurine was administered subcutaneously or intraperitoneally may be a consequence of rapid distribution or clearance. The greater anti-inflammatory effects of HEPES compared with taurine may be due to its slower distribution or clearance in-vivo.
Stapleton
P P
PP
Department of Biochemistry, Trinity College, Dublin, Ireland.
Mahon
T M
TM
Nowlan
P
P
Bloomfield
F J
FJ
D000818:Animals; D002351:Carrageenan; D004333:Drug Administration Routes; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D006531:HEPES / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006207:Half-Life; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008163:Luminescent Measurements; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013654:Taurine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D014018:Tissue Distribution
D017382:Reactive Oxygen Species; D013654:Taurine; D002351:Carrageenan; D006531:HEPES